TG Therapeutics Inc

TG Therapeutics Inc

TGTX

Get informed when a big investor buys or sells

+ Follow
Market Cap$8.25B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
TG Therapeutics IncTG Therapeutics Inc17.7-73%10.81.3
$80.50

Target Price by Analysts

49.1% upsideTG Therapeutics Target Price DetailsTarget Price
$0.44

Current Fair Value

99.2% downside

Overvalued by 99.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$8.25 Billion
Enterprise Value$8.54 Billion
Dividend Yield$- (-)
Earnings per Share$3.1
Beta1.66
Outstanding Shares141,770,283

Return

Return on Equity73.08%ROE
Return on Assets26.93%
Return on Invested Capital10.26%

Valuation & Multiples

P/E Ratio17.7P/E Ratio
PEG-24.45PEG
Price to Sales10.8Price to Sales
Price to Book Ratio13.5Price to Book Ratio
Enterprise Value to Revenue10.68
Enterprise Value to EBIT60.67
Enterprise Value to Net Income19
Total Debt to Enterprise0.09
Debt to Equity1.28Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 3, 2026
EPS Estimate
$0.31
Average shareholder expectation
Revenue Estimate
$229.77 M
Average shareholder expectation

Next Earnings Call

Expected Date
November 2, 2026
EPS Estimate
$0.36
Average shareholder expectation
Revenue Estimate
$247.06 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.6130▼ 60.78%
Total Calls2,544,793▲ 33.07%
Total Puts1,560,000▼ 33.18%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %79.42%▲ 6.42%
Total Invested$6.18B▲ 76.53%
Investors Holding462▲ 75.00%

ESG Score

No data

About TG Therapeutics Inc

CEO: Michael Weiss